AC Immune to Participate in Two Investor Conferences And Provide Scientific Updates at Aat AD PD Conference

Lausanne, Switzerland, - February 6, 2018 -AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will participate in two investor conferences in February 2018. CEO, Prof. Andrea Pfeifer will present at theLeerink Partners Annual Global Healthcare conferencein New York and the Company will participate in theCredit Suisse Global Healthcare Conferencein London

AC Immune and its collaborators will also provide five updates on the advancement of its partnered and wholly-owned product candidates and technology platform at theAAT-AD/PDTMFocus Meeting 2018in Torino, Italy, on 15-18 March 2018. The updates will cover the alpha-synuclein PET tracers, the vaccine technology of AC Immune, the anti-amyloid-ß monoclonal IgG4 antibody crenezumab, partnered with Genentech (a member of the Roche group), and the Tau-PET imaging agent, partnered with Piramal Imaging. Additionally, Dr. Andreas Muhs, CSO of AC Immune will participate in a panel addressing translational research in drug discovery for Alzheimer's disease.

Investor PresentationsLeerink Partners Annual Global Healthcare Conference, New York, USFebruary 14-15, 2018Date: February 15, 2018 | 10:30 am ETVenue: Lotte New York PalacePresenter: Prof. Andrea Pfeifer, CEO, AC ImmuneA webcast of the presentation will be available on theInvestor Pageof AC Immune's website and will be active for 90 days following the event.

Credit Suisse 2018 Global Healthcare Conference, London, UK - February 27-28, 2018CEO, Prof. Andrea Pfeifer and CFO, Joerg Hornstein will be available on both days for 1x1 meetings with investors.Venue: Credit Suisse Offices, 5 Canada Square, London

• Novel alpha-synuclein positron emission tomography (PET) tracers for the diagnosis of Parkinson's diseaseDate: March 15, 2018 | 3:40 - 4:40 pm CETPresenter: Oral presentation by Francesca Capotosti, PhD - AC Immune

• Development of highly sensitive MSD assays for the detection of anti-Abeta antibodies specific for pathological Abeta species and for Abeta peptide present on the liposomal vaccineDate: March 17, 2018 | 8:00am - 6:00pm CETPresenter: Poster presentation by Emma Fiorini, PhD - AC Immune

• Safety, tolerability and pharmacokinetics of crenezumab in mild-to-moderate AD patients treated with escalating doses for up to 32.3 monthsDate: March 15, 2018 | 8.00am - 6.00pm CETPresenter: Poster presentation by Helen Lin, PhD - Genentech

• PI-2620, Clinical evaluation of a next generation Tau-PET agent in subjects with Alzheimer's disease and progressive supranuclear palsyVenue: SALA 500Date: March 15, 2018 | 11:40 am - 12:00 CETPresenter: Oral presentation by Andrew Stephens, MD, PhD - Piramal Imaging

• Translational Research in Drug Discovery for Alzheimer's DiseaseVenue: SALA 500Date: March 15, 2018 | 3:40pm - 4:40pm CETDr. Andreas Muhs, CSO of AC Immune will participate in a forum discussion moderated by Dr. Jeffery Cummings and Ezio Giacobini.

About AC ImmuneAC Immune is a clinical stage Swiss-based biopharmaceutical company focused on neurodegenerative diseases with four product candidates in clinical trials. The Company designs, discovers and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by misfolding proteins. AC Immune's two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline features nine therapeutic and three diagnostic product candidates. The most advanced of these is crenezumab, a humanized anti-amyloid-ß monoclonal IgG4 antibody that targets monomeric and aggregated forms of amyloid-ß, with highest affinity for neurotoxic oligomers currently in Phase 3 clinical studies for AD. This global program is being conducted by the collaboration partner Genentech (a member of the Roche group). Other collaborations include Biogen, Janssen Pharmaceuticals, Nestlé Institute of Health Sciences, Piramal Imaging and Essex Bio-Technology.

Forward looking statementsThis press release contains statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions "Item 3. Key Information-Risk Factors" and "Item 5. Operating and Financial Review and Prospects" in AC Immune's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission.  Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.